Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ELI LILLY & CoLLY · Entity 2794 | Senior Vice President | December 31, 2004 | February 14, 2005 |
| HAEMONETICS CORPHAE · Entity 3953 | Director | November 08, 2018 | November 09, 2018 |
| Immunovant, Inc.HSAC · Entity 3632 | Director | May 09, 2019 | May 10, 2019 |
| Orchestra BioMed Holdings, Inc.HSAQ · Entity 434 | Director | August 03, 2020 | August 10, 2020 |
| ROCKET PHARMACEUTICALS, INC.RCKT · Entity 5627 | Director | June 18, 2025 | July 18, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ELI LILLY & Co
Report date December 31, 2004 · Filed February 14, 2005
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 106,316 |
Ending reported balance
After 2004-09-23 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2004-09-16 · Gift · Disposed 16 · Balance 106,395 Row 2 · 2004-09-23 · Gift · Disposed 79 · Balance 106,316 |
| Common StockSEC Table I · non-derivative | Indirect2002-4 GRAT | 22,760 |
Reported balance
Holding disclosure · report date 2004-12-31 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 22,760 F1: Grantor retained annuity trust established by reporting person. Reporting person is trustee. |
| Common StockSEC Table I · non-derivative | Indirect401(k) plan | 18,991 |
Reported balance
Holding disclosure · report date 2004-12-31 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 18,991 |
| Common StockSEC Table I · non-derivative | IndirectCRUT 2002 | 11,970 |
Reported balance
Holding disclosure · report date 2004-12-31 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 11,970 F2: Held by charitable remainder trust of which reporting person is trustee and sole non-charitable beneficiary. Reporting person disclaims beneficial ownership in the shares held by the CRUT, except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Indirectfamily ltd. partnership | 44,433 |
Reported balance
Holding disclosure · report date 2004-12-31 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 44,433 F3: Family limited partnership of which reporting person is sole general partner. Reporting disclaims beneficial ownership of the sh ares held by the partnership except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Grantor retained annuity trust established by reporting person. Reporting person is trustee.
F2: Held by charitable remainder trust of which reporting person is trustee and sole non-charitable beneficiary. Reporting person disclaims beneficial ownership in the shares held by the CRUT, except to the extent of his pecuniary interest therein.
F3: Family limited partnership of which reporting person is sole general partner. Reporting disclaims beneficial ownership of the sh ares held by the partnership except to the extent of his pecuniary interest therein.
HAEMONETICS CORP
Report date November 08, 2018 · Filed November 09, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,335 |
Reported balance
After 2018-11-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-11-08 · Sale · Disposed 12,322 · Balance 15,335 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.50 to $114.60, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F2: This number includes unvested restricted stock units previously reported. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.50 to $114.60, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F2: This number includes unvested restricted stock units previously reported.
Immunovant, Inc.
Report date May 09, 2019 · Filed May 10, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy way of Health Sciences Holdings, LLC. | 20,000 |
Reported balance
Holding disclosure · report date 2019-05-09 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 20,000 |
Orchestra BioMed Holdings, Inc.
Report date August 03, 2020 · Filed August 10, 2020 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 22,261 |
Reported balance
Holding disclosure · report date 2020-08-03 · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · Balance 22,261 |
ROCKET PHARMACEUTICALS, INC.
Report date June 18, 2025 · Filed July 18, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,000 |
Reported balance
After 2025-06-18 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-06-18 · Grant · Acquired 30,000 · Balance 30,000 F1: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2026. |
| Common StockSEC Table I · non-derivative | Direct | 54,734 |
Reported balance
After 2025-06-18 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2025-06-18 · Grant · Acquired 24,734 · Balance 54,734 F1: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2026. F2: Represents RSUs issued to the Reporting Person in lieu of director retainer fees of $70,000. The RSUs will vest in full on June 18, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2026.
F2: Represents RSUs issued to the Reporting Person in lieu of director retainer fees of $70,000. The RSUs will vest in full on June 18, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 18, 2025 Filed Jul 18, 2025 20:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantCommon Stock | 24,734 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-25-026410 · form4.xml · nonDerivative · entry 2 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,734 F1 · security: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2026. F2 · security: Represents RSUs issued to the Reporting Person in lieu of director retainer fees of $70,000. The RSUs will vest in full on June 18, 2026. F1 · price: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2026. Read SEC document |
| June 18, 2025 Filed Jul 18, 2025 20:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-25-026410 · form4.xml · nonDerivative · entry 1 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 F1 · security: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2026. F1 · price: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2026. Read SEC document |
| June 13, 2024 Filed Jun 20, 2024 20:10 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 4,655 | $15.04 Strike: $22.86 | $70,011.20 |
DisclosureSEC source: 0001140361-24-030724 · form4.xml · derivative · entry 2 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,655 Underlying: Common Stock · 4,655 shares Expires 2034-06-13 F2 · derivative.exercise_date: This option represents a right to purchase a total of 4,655 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 13, 2025. This option was issued to the Reporting Person in lieu of director retainer fees of $70,000. Read SEC document |
| June 13, 2024 Filed Jun 20, 2024 20:10 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 23,944 | $0.00 Strike: $22.86 | $0.00 |
DisclosureSEC source: 0001140361-24-030724 · form4.xml · derivative · entry 1 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,944 Underlying: Common Stock · 23,944 shares Expires 2034-06-13 F1 · derivative.exercise_date: This option represents a right to purchase a total of 23,944 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 13, 2025. Read SEC document |
| June 22, 2023 Filed Jun 26, 2023 23:47 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 5,026 | $13.93 Strike: $21.56 | $70,012.18 |
DisclosureSEC source: 0001140361-23-031527 · form4.xml · derivative · entry 2 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,026 Underlying: Common Stock · 5,026 shares Expires 2033-06-22 F2 · derivative.exercise_date: This option represents a right to purchase a total of 5,026 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 22, 2024. This option was issued to the Reporting Person in lieu of director retainer fees of $70,000. Read SEC document |
| June 22, 2023 Filed Jun 26, 2023 23:47 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 25,850 | $0.00 Strike: $21.56 | $0.00 |
DisclosureSEC source: 0001140361-23-031527 · form4.xml · derivative · entry 1 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,850 Underlying: Common Stock · 25,850 shares Expires 2033-06-22 F1 · derivative.exercise_date: This option represents a right to purchase a total of 25,850 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 22, 2024. Read SEC document |
| June 13, 2022 Filed Jun 16, 2022 01:07 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 10,283 | $6.80 Strike: $10.77 | $69,924.40 |
DisclosureSEC source: 0001140361-22-023147 · form4.xml · derivative · entry 2 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,283 Underlying: Common Stock · 10,283 shares Expires 2032-06-13 F2 · derivative.exercise_date: This option represents a right to purchase a total of 10,283 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 13, 2023. This option was issued to the Reporting Person in lieu of director retainer fees of $70,000. Read SEC document |
| June 13, 2022 Filed Jun 16, 2022 01:07 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 47,745 | $0.00 Strike: $10.77 | $0.00 |
DisclosureSEC source: 0001140361-22-023147 · form4.xml · derivative · entry 1 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,745 Underlying: Common Stock · 47,745 shares Expires 2032-06-13 F1 · derivative.exercise_date: This option represents a right to purchase a total of 47,745 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 13, 2023. Read SEC document |
| June 14, 2021 Filed Jun 17, 2021 00:19 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 2,379 | $29.42 Strike: $47.25 | $69,990.18 |
DisclosureSEC source: 0001140361-21-021305 · form4.xml · derivative · entry 2 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,379 Underlying: Common Stock · 2,379 shares Expires 2031-06-14 F2 · derivative.exercise_date: This option represents a right to purchase a total of 2,379 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 14, 2022. This option was issued to the Reporting Person in lieu of director retainer fees of $70,000. Read SEC document |
| June 14, 2021 Filed Jun 17, 2021 00:19 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 12,236 | $0.00 Strike: $47.25 | $0.00 |
DisclosureSEC source: 0001140361-21-021305 · form4.xml · derivative · entry 1 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,236 Underlying: Common Stock · 12,236 shares Expires 2031-06-14 F1 · derivative.exercise_date: This option represents a right to purchase a total of 12,236 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 14, 2022. Read SEC document |
| December 28, 2020 Filed Feb 17, 2021 02:57 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GiftStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $19.90 | $0.00 |
DisclosureSEC source: 0001140361-21-005130 · form5.xml · derivative · entry 6 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Paul Andrew Granadillo 2020 Irrevocable Trust dated 12/28/2020 Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-06-16 F3 · derivative.exercise_date: This option represents a right to purchase a total of 20,000 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 16, 2021. Read SEC document |
| December 28, 2020 Filed Feb 17, 2021 02:57 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GiftStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $19.90 | $0.00 |
DisclosureSEC source: 0001140361-21-005130 · form5.xml · derivative · entry 5 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2030-06-16 F3 · derivative.exercise_date: This option represents a right to purchase a total of 20,000 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 16, 2021. Read SEC document |
| December 28, 2020 Filed Feb 17, 2021 02:57 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GiftStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $18.75 | $0.00 |
DisclosureSEC source: 0001140361-21-005130 · form5.xml · derivative · entry 4 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Ann Granadillo Lowe 2020 Revocable Trust dated 12/28/2020 Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2028-03-29 F2 · derivative.exercise_date: This option represents a right to purchase a total of 40,000 shares of the Issuer's Common Stock, 37,778 of which are currently vested and exercisable, with the remaining 2,222 shares vesting in equal monthly installments on each of February 28, 2021 and March 29, 2021. Read SEC document |
| December 28, 2020 Filed Feb 17, 2021 02:57 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GiftStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $18.75 | $0.00 |
DisclosureSEC source: 0001140361-21-005130 · form5.xml · derivative · entry 3 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2028-03-29 F2 · derivative.exercise_date: This option represents a right to purchase a total of 40,000 shares of the Issuer's Common Stock, 37,778 of which are currently vested and exercisable, with the remaining 2,222 shares vesting in equal monthly installments on each of February 28, 2021 and March 29, 2021. Read SEC document |
| December 28, 2020 Filed Feb 17, 2021 02:57 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GiftStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $14.56 | $0.00 |
DisclosureSEC source: 0001140361-21-005130 · form5.xml · derivative · entry 2 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Ann Granadillo Lowe 2020 Revocable Trust dated 12/28/2020 Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-01-28 F1 · derivative.exercise_date: This option represents a right to purchase a total of 30,000 shares of the Issuer's Common Stock, all of which are currently vested and exercisable. Read SEC document |
| December 28, 2020 Filed Feb 17, 2021 02:57 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GiftStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $14.56 | $0.00 |
DisclosureSEC source: 0001140361-21-005130 · form5.xml · derivative · entry 1 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2029-01-28 F1 · derivative.exercise_date: This option represents a right to purchase a total of 30,000 shares of the Issuer's Common Stock, all of which are currently vested and exercisable. Read SEC document |
| June 16, 2020 Filed Jun 19, 2020 01:40 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $19.90 | $0.00 |
DisclosureSEC source: 0001140361-20-014243 · form4.xml · derivative · entry 1 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-06-16 F1 · derivative.exercise_date: This option represents a right to purchase a total of 20,000 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 16, 2021. Read SEC document |
| January 28, 2019 Filed Jan 30, 2019 23:40 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $14.56 | $0.00 |
DisclosureSEC source: 0001140361-19-002013 · form4.xml · derivative · entry 1 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-01-28 F1 · derivative.exercise_date: This option represents a right to purchase a total of 30,000 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on January 28, 2020. Read SEC document |
| November 08, 2018 Filed Nov 9, 2018 21:10 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 12,322 | $114.50 | $1,410,869.00 |
DisclosureSEC source: 0001127602-18-032638 · form4.xml · nonDerivative · entry 1 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,335 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.50 to $114.60, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| September 17, 2018 Filed Sep 19, 2018 21:00 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 10,353 | $0.00 Strike: $35.50 | $0.00 |
DisclosureSEC source: 0001127602-18-028076 · form4.xml · derivative · entry 11 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,353 shares Expires 2021-07-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F8 · derivative.exercise_date: Grant to reporting person of right to buy shares of common stock exercisable 100 percent on the first anniversary of the date of grant. Read SEC document |
| September 17, 2018 Filed Sep 19, 2018 21:00 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 6,573 | $0.00 Strike: $45.45 | $0.00 |
DisclosureSEC source: 0001127602-18-028076 · form4.xml · derivative · entry 10 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,573 shares Expires 2020-07-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F8 · derivative.exercise_date: Grant to reporting person of right to buy shares of common stock exercisable 100 percent on the first anniversary of the date of grant. Read SEC document |
| September 17, 2018 Filed Sep 19, 2018 21:00 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 8,196 | $0.00 Strike: $36.37 | $0.00 |
DisclosureSEC source: 0001127602-18-028076 · form4.xml · derivative · entry 9 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,196 shares Expires 2019-07-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F8 · derivative.exercise_date: Grant to reporting person of right to buy shares of common stock exercisable 100 percent on the first anniversary of the date of grant. Read SEC document |
| September 17, 2018 Filed Sep 19, 2018 21:00 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 631 | $114.16 | $72,034.96 |
DisclosureSEC source: 0001127602-18-028076 · form4.xml · nonDerivative · entry 8 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,657 F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114 to $114.44, inclusive. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| September 17, 2018 Filed Sep 19, 2018 21:00 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 11,812 | $113.16 | $1,336,645.92 |
DisclosureSEC source: 0001127602-18-028076 · form4.xml · nonDerivative · entry 7 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,288 F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.51 to $113.35, inclusive. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| September 17, 2018 Filed Sep 19, 2018 21:00 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 13,183 | $111.33 | $1,467,663.39 |
DisclosureSEC source: 0001127602-18-028076 · form4.xml · nonDerivative · entry 6 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,100 F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.92 to 111.88, inclusive. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| September 17, 2018 Filed Sep 19, 2018 21:00 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 3,696 | $110.11 | $406,966.56 |
DisclosureSEC source: 0001127602-18-028076 · form4.xml · nonDerivative · entry 5 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,283 F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.79 to $110.55, inclusive. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| September 17, 2018 Filed Sep 19, 2018 21:00 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 1,502 | $108.92 | $163,597.84 |
DisclosureSEC source: 0001127602-18-028076 · form4.xml · nonDerivative · entry 4 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,979 F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.61 to $109.33, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (7) to this Form 4. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| September 17, 2018 Filed Sep 19, 2018 21:00 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionCommon Stock | 10,353 | $35.50 | $367,531.50 |
DisclosureSEC source: 0001127602-18-028076 · form4.xml · nonDerivative · entry 3 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,481 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| September 17, 2018 Filed Sep 19, 2018 21:00 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionCommon Stock | 6,573 | $45.45 | $298,742.85 |
DisclosureSEC source: 0001127602-18-028076 · form4.xml · nonDerivative · entry 2 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,128 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| September 17, 2018 Filed Sep 19, 2018 21:00 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionCommon Stock | 8,196 | $36.37 | $298,088.52 |
DisclosureSEC source: 0001127602-18-028076 · form4.xml · nonDerivative · entry 1 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| July 26, 2018 Filed Jul 30, 2018 22:16 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 1,696 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-024059 · form4.xml · nonDerivative · entry 1 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,359 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan (as amended). The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| March 29, 2018 Filed Apr 3, 2018 00:16 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $18.75 | $0.00 |
DisclosureSEC source: 0000899243-18-009124 · doc4.xml · derivative · entry 1 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2028-03-29 F1 · derivative.exercise_date: This option represents a right to purchase a total of 40,000 shares of the Issuer's Common Stock, 13,336 of which will become fully vested and exercisable on March 29, 2019, with the remaining 26,664 shares vesting in equal monthly installments over the following two years. Read SEC document |
| December 01, 2017 Filed Dec 4, 2017 21:14 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 7,118 | $0.00 Strike: $34.41 | $0.00 |
DisclosureSEC source: 0001127602-17-033796 · form4.xml · derivative · entry 23 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,118 shares Expires 2018-07-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Grant to reporting person of right to buy shares of common stock exercisable 100 percent on the first anniversary of the date of grant. Read SEC document |
| December 01, 2017 Filed Dec 4, 2017 21:14 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 40 | $57.10 | $2,284.00 |
DisclosureSEC source: 0001127602-17-033796 · form4.xml · nonDerivative · entry 22 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,381 Read SEC document |
| December 01, 2017 Filed Dec 4, 2017 21:14 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 200 | $57.09 | $11,418.00 |
DisclosureSEC source: 0001127602-17-033796 · form4.xml · nonDerivative · entry 21 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,421 Read SEC document |
| December 01, 2017 Filed Dec 4, 2017 21:14 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 200 | $57.08 | $11,416.00 |
DisclosureSEC source: 0001127602-17-033796 · form4.xml · nonDerivative · entry 20 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,621 Read SEC document |
| December 01, 2017 Filed Dec 4, 2017 21:14 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 100 | $57.07 | $5,707.49 |
DisclosureSEC source: 0001127602-17-033796 · form4.xml · nonDerivative · entry 19 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,821 Read SEC document |
| December 01, 2017 Filed Dec 4, 2017 21:14 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 760 | $57.07 | $43,373.20 |
DisclosureSEC source: 0001127602-17-033796 · form4.xml · nonDerivative · entry 18 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,921 Read SEC document |
| December 01, 2017 Filed Dec 4, 2017 21:14 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 200 | $57.06 | $11,412.00 |
DisclosureSEC source: 0001127602-17-033796 · form4.xml · nonDerivative · entry 17 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,681 Read SEC document |
| December 01, 2017 Filed Dec 4, 2017 21:14 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 4,100 | $57.06 | $233,925.50 |
DisclosureSEC source: 0001127602-17-033796 · form4.xml · nonDerivative · entry 16 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,881 Read SEC document |
| December 01, 2017 Filed Dec 4, 2017 21:14 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 9 | $57.05 | $513.45 |
DisclosureSEC source: 0001127602-17-033796 · form4.xml · nonDerivative · entry 15 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,981 Read SEC document |
| December 01, 2017 Filed Dec 4, 2017 21:14 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 100 | $57.03 | $5,703.00 |
DisclosureSEC source: 0001127602-17-033796 · form4.xml · nonDerivative · entry 14 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,990 Read SEC document |
| December 01, 2017 Filed Dec 4, 2017 21:14 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 91 | $57.02 | $5,188.82 |
DisclosureSEC source: 0001127602-17-033796 · form4.xml · nonDerivative · entry 13 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,090 Read SEC document |
| December 01, 2017 Filed Dec 4, 2017 21:14 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 100 | $57.02 | $5,701.50 |
DisclosureSEC source: 0001127602-17-033796 · form4.xml · nonDerivative · entry 12 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,181 Read SEC document |
| December 01, 2017 Filed Dec 4, 2017 21:14 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 100 | $57.01 | $5,700.70 |
DisclosureSEC source: 0001127602-17-033796 · form4.xml · nonDerivative · entry 11 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,281 Read SEC document |
| December 01, 2017 Filed Dec 4, 2017 21:14 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 100 | $57.01 | $5,700.50 |
DisclosureSEC source: 0001127602-17-033796 · form4.xml · nonDerivative · entry 10 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,381 Read SEC document |
| December 01, 2017 Filed Dec 4, 2017 21:14 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 300 | $57.00 | $17,100.00 |
DisclosureSEC source: 0001127602-17-033796 · form4.xml · nonDerivative · entry 9 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,481 Read SEC document |
| December 01, 2017 Filed Dec 4, 2017 21:14 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionCommon Stock | 7,118 | $34.41 | $244,894.79 |
DisclosureSEC source: 0001127602-17-033796 · form4.xml · nonDerivative · entry 8 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,781 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2017 Filed Dec 4, 2017 21:14 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 100 | $57.13 | $5,712.50 |
DisclosureSEC source: 0001127602-17-033796 · form4.xml · nonDerivative · entry 7 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,281 Read SEC document |
| December 01, 2017 Filed Dec 4, 2017 21:14 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 100 | $57.13 | $5,713.00 |
DisclosureSEC source: 0001127602-17-033796 · form4.xml · nonDerivative · entry 6 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,181 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.